@ 013/014

Attorney Docket No.: DOC-0216US (ISIS:003CP1) USSN 10/712,795

REMARKS AND ELECTIONS

Claims 1-108 are canceled and claims 109-192 are newly introduced. Support for the newly introduced claims is found throughout the specification, including in the claims as originally filed. Additionally, support for "up to two mismatches" in newly added claim 109 is found, for example, on page 206, in Table 33 and on pages 223-224, Table 44 and following paragraph.

The Examiner asserts that the originally-filed claims should be divided into the two following groups:

- I. Claims 1-35, 66-70, 97-108 drawn to compounds 8 to 50 nucleobases in length targeted to a nucleic acid encoding human apolipoprotein wherein said compound specifically hybridizes to nucleotides 2920-3420, or 3230-3288 of SEQ ID NO: 3, or SEQ ID NO: 247.
- II. Claims 36-65, 71-96 drawn to methods of inhibiting the expression of apolipoprotein B in cells, and a method of treating an animal having a disease or condition associated with apolipoprotein B.

New claims 109-141 are drawn to compounds and targeted to a nucleic acid encoding apolipoprotein B, whereas claims 142-192 are drawn to methods of using compounds targeted to a nucleic acid encoding apolipoprotein B. Applicants believe that the election of claims 109-141 would correspond to the election of the claims of group I as set out by the Examiner. Accordingly, Applicants hereby elect claims 109-141, drawn to compounds targeted to a nucleic acid encoding apolipoprotein B.

2014/014

Attorney Docket No.: DOC-0216US (I\$1\$.003CP1)

USSN 10/712,795

CONCLUSIONS

ISIS PATENT DEPT

In view of these amendments and elections, Applicants believe that the case is now in proper form for examination. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 50-0252.

A prompt office action on the merits of the case is requested.

Respectfully submitted,

Frances R. Putkey, Ph.D. Agent for Applicant Registration No. 57,257

Telephone: (760) 931-9200 Facsimile: (760) 603-3820